Progyny (NASDAQ: PGNY) updates Q4 and 2025 financial guidance

Rhea-AI Filing Summary

Progyny, Inc. furnished an update to its previously issued financial guidance for the three months and full year ending December 31, 2025. The company did this by issuing a press release dated January 12, 2026, which is attached as Exhibit 99.1 to this Form 8-K and incorporated by reference into the disclosure under Item 2.02. The information in this item and the exhibit is being furnished rather than filed under securities laws, meaning it is not subject to certain liability provisions and is not automatically incorporated into other regulatory documents.

Insights

Equity research analyst

Progyny updates Q4 and 2025 guidance via a furnished press release, but details are in the exhibit, not here.

Progyny, Inc. has updated its previously issued financial guidance for both the quarter and full year ending December 31, 2025, and communicated this through a press release furnished with the Form 8-K. Guidance changes often reflect shifts in expected revenue or profitability, but this excerpt does not describe the direction or magnitude of the revisions, so the commercial impact must be taken from the press release itself.

The company explicitly characterizes the information as furnished rather than filed, which limits certain legal exposures and prevents automatic incorporation into other regulatory documents. From an investor perspective, the key data points are contained in Exhibit 99.1; subsequent periodic reports for periods including December 31, 2025 will show how actual results compared with this updated outlook.

0001551306false00015513062026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Progyny, Inc.

(Exact name of Registrant as Specified in Charter)

Delaware			001-39100			27-2220139
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

1359 Broadway New York, New York			10018
(Address of Principal Executive Offices)			(Zip Code)

(212) 888-3124

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

PGNY

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, Progyny, Inc. (the “Company”) issued a press release to update the Company’s previously issued financial guidance for the three months and year ending December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release of Progyny, Inc. dated January 12, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Progyny, Inc.
Dated: January 12, 2026
			By:			/s/ Peter Anevski
						Peter Anevski
						Chief Executive Officer

FAQ

What did Progyny (PGNY) disclose in this Form 8-K?

Progyny, Inc. disclosed that it issued a press release updating its previously issued financial guidance for the three months and year ending December 31, 2025, and furnished that release as Exhibit 99.1.

Which periods does Progyny (PGNY) say it updated guidance for?

Progyny states that the updated financial guidance covers the three months ending December 31, 2025 and the full year ending December 31, 2025.

How did Progyny (PGNY) provide its updated 2025 financial guidance?

Progyny provided the updated 2025 financial guidance through a press release dated January 12, 2026, which is attached to the Form 8-K as Exhibit 99.1 and incorporated by reference into Item 2.02.

Is Progyny’s updated guidance information considered filed with the SEC?

No. Progyny specifies that the information in Item 2.02 of the Form 8-K and Exhibit 99.1 is furnished, not filed, so it is not subject to Section 18 liability and is not deemed incorporated into other SEC filings.

Who signed this Progyny (PGNY) Form 8-K?

The Form 8-K was signed on behalf of Progyny, Inc. by Peter Anevski, who is identified as the company’s Chief Executive Officer.

What exhibits are attached to this Progyny (PGNY) Form 8-K?

The Form 8-K lists Exhibit 99.1, the Progyny, Inc. press release dated January 12, 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.